A Phase I/II Study to Assess the Safety and Efficacy of MultiStem Cell Therapy in Subjects with Acute Respiratory Distress Syndrome

Brief Description Of Study

Acute Respiratory Distress Syndrome (ARDS) is an acute injury to the lungs that causes severely low blood oxygen levels and requires a ventilator. No drug treatment currently exists for ARDS. The purpose of this study is to test the safety and tolerability of MultiStem® therapy for the treatment of moderate to severe ARDS. MultiStem therapy is an investigational medicinal product (IMP) taken from the bone marrow of a non-related donor, expanded outside the body and banked according to defined criteria. MultiStem therapy may reduce inflammation and help the lungs to heal. This product has previously been administered to over 200 subjects in other investigational trials and it was safe and well tolerated. Eligible subjects will have moderate to severe ARDS despite adequate ventilator therapy. Subjects will receive either a one-time infusion of MultiStem® therapy or a placebo, an inactive drug, while on a ventilator in the intensive care unit. The patients vital signs and laboratory values will be carefully monitored according to best clinical practices for ARDS. The study will record any potential adverse events and will monitor subjects survival, time on the ventilator, and physiologic data.

Clinical Study Identifier: 02611609


Contact research investigator to learn more about this study by filling out the form below.


To: Research Study Investigator
Subject: I am interested in participating in your Research Study
Dear Investigator,
I'm interested in learning more about and participating in your research study named: A Phase I/II Study to Assess the Safety and Efficacy of MultiStem Cell Therapy in Subjects with Acute Respiratory Distress Syndrome
I am hoping to hear back from you and discuss details of the study

By clicking "Contact Research Team", your contact information will be sent directly to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.